Endometrial bleeding in postmenopausal women: With and without hormone therapy

Menopause

Volumn 18, Issue 4, 2011, Pages 416-420

  Archer, David F ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b NONE   (United States)

Author keywords

Angiogenesis; Estrogen progestin therapy; Metalloproteinases; Pericytes; Postmenopausal bleeding

Indexed keywords

ANGIOGENIC FACTOR; BAZEDOXIFENE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; LEVONORGESTREL; METALLOPROTEINASE; NORETHISTERONE; THROMBOSPONDIN 1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CONFERENCE PAPER; ESTROGEN THERAPY; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; MENSTRUATION; METRORRHAGIA; MORPHOLOGY; PERICYTE; POSTMENOPAUSE; UTERUS BLEEDING; VASCULAR FRAGILITY;

ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; METRORRHAGIA; POSTMENOPAUSE;

EID: 79955013440     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820ca808     Document Type: Conference Paper

References (52)

1. Staland B. Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 1981;3: 145-156. (Pubitemid 11021569)
2. Staland B. Continuous treatment with a combination of estrogen and gestagenVa way of avoiding endometrial stimulation. Clinical experiences with Kliogest. Acta Obstet Gynecol Scand 1985;130:29-35. (Pubitemid 15058114)
3. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-1087. (Pubitemid 32522601)
4. Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999;94: 323-329. (Pubitemid 29393063)
5. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-727. (Pubitemid 41669124)
6. Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003;188:92-99. (Pubitemid 36135603)
7. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. Obstet Gynecol 2000;96: 366-372.
8. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 2006;53:413-423.
9. Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiolnorethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498-503. (Pubitemid 29460929)
10. Sturdee DW, Archer DF, Rakov V, Lang E. Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. Climacteric 2008;11:63-73.
11. Hickey M, Pillai G, Higham JM, et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapyrelated irregular bleeding. Hum Reprod 2003;18:1100-1106. (Pubitemid 36592056)
12. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. BMJ 2002;325:239.
13. Wallach EE. Physiology of menstruation. Clin Obstet Gynecol 1970;13: 366-385.
14. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-1115.
15. Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-1404. (Pubitemid 40734275)
16. Goldstein SR, Neven P, Cummings S, et al. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene trial: 5-year gynecological outcomes. Menopause 2011;18:17-22.
17. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging 2010;27:533-544.
18. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102-1108.
19. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-1044.
20. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. JAMA 1996;276:1397-1403. (Pubitemid 26365845)
21. Pickar JH, Yeh I, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;76:25-31. (Pubitemid 32600955)
22. Kurman RJ, Felix JC, Archer DF, Nanavati N, Arce J, Moyer DL. Norethindrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 2000;96:373-379.
23. Okeahialam MG, Jones SE, O'Donovan PJ. Outcome of outpatient micro-hysteroscopy performed for abnormal bleeding while on hormone replacement therapy. J Obstet Gynaecol 2001;21:277-279. (Pubitemid 32578907)
24. Domingues AP, Lopes H, Dias I, De Oliveira CF. Endometrial polyps in postmenopausal women. Acta Obstet Gynecol Scand 2009;88: 618-620.
25. Vani S, Critchley HO, Fraser IS, Hickey M. Endometrial expression of steroid receptors in postmenopausal hormone replacement therapy users: relationship to bleeding patterns. J Fam Plann Reprod Health Care 2008; 34:27-34.
26. Joness RL, Morison NB, Hannan NJ, Critchley HO, Salamonsen LA. Chemokine expression is dysregulated in the endometrium of women using progestin-only contraceptives and correlates to elevated recruitment of distinct leukocyte populations. Hum Reprod 2005;20:2724-2735. (Pubitemid 41487626)
27. Clark DA, Wang S, Rogers P, Vince G, Affandi B. Endometrial lymphomyeloid cells in abnormal uterine bleeding due to levonorgestrel (Norplant). Hum Reprod 1996;11:1438-1444. (Pubitemid 26335092)
28. Ludwig H. The morphologic response of the human endometrium to long-term treatment with progestational agents. Am J Obstet Gynecol 1982;142:796-808. (Pubitemid 12135905)
29. Geppert M, Geppert J. Lymphocytes in the epithelial layers of decidua and normal or abnormal endometrium. Arch Gynecol 1982;233:47-51. (Pubitemid 13187571)
30. Al-Jefout M, Black K, Schulke L, et al. Novel finding of high density of activated mast cells in endometrial polyps. Fertil Steril 2009;92:1104-1106.
31. Hickey M, Crewe J, Goodridge JP, et al. Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells? J Clin Endocrinol Metab 2005;90:5528-5535. (Pubitemid 41415454)
32. Thomas AM, Hickey M, Fraser IS. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 2000;15:7-17.
33. Archer DF, Navarro FJ, Leslie S, Mirkin S. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17A-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004;81:165-170. (Pubitemid 38058343)
34. Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17A-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 2004;82:220-222. (Pubitemid 38968804)
35. Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric 2003;6:273-277. (Pubitemid 38112896)
36. Charnock-Jones DS, Macpherson AM, Archer DF, et al. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 2000;15:85-95.
37. Hickey M, Doherty DA, Fraser IS, Sloboda DM, Salamonsen LA. Why does menopausal hormone therapy lead to irregular uterine bleeding? Changes to endometrial blood vessels. Hum Reprod 2008;23:912-918.
38. Hickey M, Dwarte D, Fraser IS. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 2000;15:1509-1514.
39. Gerhardt H, Golding M, Fruttiger M, et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003;161: 1163-1177. (Pubitemid 36870177)
40. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res 2003;314:15-23. (Pubitemid 37409909)
41. Richards OC, Raines SM, Attie AD. The role of blood vessels, endothelial cells, and vascular pericytes in insulin secretion and peripheral insulin action. Endocr Rev 2010;31:343-363.
42. Hellstrom M, Gerhardt H, Kalen M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001;153:543-553. (Pubitemid 34280141)
43. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-674. (Pubitemid 27193480)
44. Xian X, Hakansson J, Stahlberg A, et al. Pericytes limit tumor cell metastasis. J Clin Invest 2006;116:642-651. (Pubitemid 43326873)
45. Booker SS, Jayanetti C, Karalak S, Hsiu JG, Archer DF. The effect of progesterone on the accumulation of leukocytes in the human endometrium. Am J Obstet Gynecol 1994;171:139-142. (Pubitemid 24254431)
46. Salamonsen LA, Woolley DE. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J Reprod Immunol 1999;44:1-27. (Pubitemid 29457769)
47. Salamonsen LA, Zhang J, Brasted M. Leukocyte networks and human endometrial remodelling. J Reprod Immunol 2002;57:95-108. (Pubitemid 35245742)
48. Salamonsen LA, Lathbury LJ. Endometrial leukocytes and menstruation. Hum Reprod Update 2000;6:16-27. (Pubitemid 30099339)
49. Salamonsen LA. Current concepts of the mechanisms of menstruation: a normal process of tissue destruction. Trends Endocrinol Metab 1998;9: 305-309. (Pubitemid 28471339)
50. Salamonsen LA, Woolley DE. Matrix metalloproteinases in normal menstruation. Hum Reprod 1996;11:124-133.
51. Zhao S, Choksuchat C, Zhao Y, Ballagh SA, Kovalevsky GA, Archer DF. Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant. Contraception 2009;79:469-478.
52. HickeyM, Crewe J,Mahoney LA, Doherty DA, Fraser IS, Salamonsen LA. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 2006;91:3189-3198. (Pubitemid 44271775)